Infective endocarditis prevention resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
'''For infective endocarditis resident survival guide click [[infective endocarditis resident survival guide|here]].'''
{{CMG}}; {{AE}} {{MM}}; {{Rim}}
{{CMG}}; {{AE}} {{MM}}; {{Rim}}


==Overview==
==Overview==
Prevention of [[infective endocarditis]] can be achieved through the administration of antiobiotic prophylaxis to high risk subjects who are undergoing high risk procedures.  The choice of antibiotic prophylaxis depends on whether the subject can tolerate oral intake or not, as well as on whether patient has aspirin allergy or not.
Prevention of [[infective endocarditis]] can be achieved through the administration of antiobiotic prophylaxis to high risk subjects who are undergoing high risk procedures.  The choice of antibiotic prophylaxis depends on whether the subject can tolerate oral intake or not, as well as on whether patient has allergy to [[penicillin]] or not.


==Prevention==
==Prevention==
Line 35: Line 37:


===Antibiotic Prophylaxis===
===Antibiotic Prophylaxis===
Shown below is a table depicting the prophylaxis antibiotic regimes for [[infective endocarditis]].<ref name="circ.ahajournals.org">{{Cite web  | last =  | first =  | title = 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary | url = http://circ.ahajournals.org/content/early/2014/02/27/CIR.0000000000000029.citation | publisher =  | date =  | accessdate = 4 March 2014 }}</ref>
Shown below is an algorithm depicting the prophylaxis antibiotic regimens for [[infective endocarditis]].<ref name="circ.ahajournals.org">{{Cite web  | last =  | first =  | title = 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary | url = http://circ.ahajournals.org/content/early/2014/02/27/CIR.0000000000000029.citation | publisher =  | date =  | accessdate = 4 March 2014 }}</ref>


{| style="background: #FFFFFF;"
{{Family tree/start}}
| valign=top |
{{familytree | | | | | | | A01 | | | | |  A01= '''Does the patient have allergy to penicillin?'''}}
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
{{familytree | | | |,|-|-|-|^|-|-|-|.| | }}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center colspan="2"| {{fontcolor|#FFF|Infective Endocarditis Antibiotic Prophylaxis}}
{{familytree | | | B01 | | | | | | B02 | B01= '''NO''' |B02= '''Yes'''}}
|-
{{familytree | | | |!| | | | | | | |!| | }}
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Oral treatment is tolerated'''''
{{familytree | | | C01 | | | | | | C02 | C01= '''Does the patient tolerate oral therapy?'''| C02= '''Does the patient tolerate oral therapy?'''}}
|-
{{familytree | |,|-|^|-|.| | | |,|-|^|-|.| |}}
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left | '''''Not allergic to penicillin'''''|| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left|'''''Allergic to penicillin'''''
{{familytree | D01 | | D02 | | D03 | | D04 | D01= '''YES'''| D02= '''NO''' | D03= '''YES'''| D04= '''NO'''}}
|-
{{familytree | |!| | | |!| | | |!| | | |!| | }}
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left |▸ '''''[[Amoxicillin]] 2 g'''''|| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left|▸ '''''[[Ampicillin]] 2 g IM or IV'''''<br> ''OR'' <br>'''''[[Cefazolin]] 1 g IM or IV''''' <br> ''OR'' <br>'''''[[Ceftriaxone]] 1 g IM or IV'''''
{{familytree | E01 | | E02 | | E03 | | E04 | E01= '''''[[Amoxicillin]] 2 g'''''| E02= '''''[[Cefalexin]] 2 g''''' <br> ''OR'' <br>'''''[[Clindamycin]] 600 mg''''' <br> ''OR'' <br>'''''[[Azithromycin]] 500 mg''''' <br> ''OR'' <br>❑ '''''[[Clarithromycin]] 500 mg'''''| E03='''''[[Ampicillin]] 2 g IM or IV'''''<br> ''OR'' <br>'''''[[Cefazolin]] 1 g IM or IV''''' <br> ''OR'' <br>'''''[[Ceftriaxone]] 1 g IM or IV''''' | E04= '''''[[Cefazolin]] 1 g IM or IV''''' <br> ''OR'' <br>'''''[[Ceftriaxone]] 1 g IM or IV'''''<br> ''OR'' <br>'''''[[Clindamycin]] 600 mg IM or IV'''''}}
|-
{{Family tree/end}}
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Oral treatment is not tolerated'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left | '''''Not allergic to penicillin'''''|| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left|'''''Allergic to penicillin'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left |▸ '''''[[Cefalexin]] 2 g''''' <br> ''OR'' <br>'''''[[Clindamycin]] 600 mg''''' <br> ''OR'' <br>'''''[[Azithromycin]] 500 mg''''' <br> ''OR'' <br>▸ '''''[[Clarithromycin]] 500 mg''''' || style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left|▸ '''''[[Cefazolin]] 1 g IM or IV''''' <br> ''OR'' <br>'''''[[Ceftriaxone]] 1 g IM or IV'''''<br> ''OR'' <br>'''''[[Clindamycin]] 600 mg IM or IV'''''
|-
|}
|}


==References==
==References==

Latest revision as of 21:09, 6 May 2014

For infective endocarditis resident survival guide click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]; Rim Halaby, M.D. [3]

Overview

Prevention of infective endocarditis can be achieved through the administration of antiobiotic prophylaxis to high risk subjects who are undergoing high risk procedures. The choice of antibiotic prophylaxis depends on whether the subject can tolerate oral intake or not, as well as on whether patient has allergy to penicillin or not.

Prevention

Shown below is an algorithm depicting the general prophylactic approaches of infective endocarditis.[1][2]

Identify high risk patients: (Class IIa, Level of evidence B)

Prosthetic valves patients
❑ Previous infective endocarditis
Cardiac transplant recipients with valves regurgitation due to structurally abnormal valve
Congenital heart diseases

❑ Unrepaired cyanotic congenital heart diseases
❑ Completely repaired defect with prosthetic material or device
❑ Repaired with residual defects
 
 
 
 
 
 
Identify high risk procedures:

Dental procedures

❑ Manipulation of gingival tissue, or
❑ Manipulation of the periapical region of teeth, or
❑ Perforation of the oral mucosa

Respiratory tract procedures involving incision of the respiratory tract mucosa

Tonsillectomy
Adenoidectomy

Gastrointestinal (GI) and genitourinary (GU) procedures only if GI or GU tract infection is present

 
 
 
 
 
 
❑ Administer prophylaxis
 

Antibiotic Prophylaxis

Shown below is an algorithm depicting the prophylaxis antibiotic regimens for infective endocarditis.[2]

 
 
 
 
 
 
Does the patient have allergy to penicillin?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NO
 
 
 
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient tolerate oral therapy?
 
 
 
 
 
Does the patient tolerate oral therapy?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES
 
NO
 
YES
 
NO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amoxicillin 2 g
 
Cefalexin 2 g
OR
Clindamycin 600 mg
OR
Azithromycin 500 mg
OR
Clarithromycin 500 mg
 
Ampicillin 2 g IM or IV
OR
Cefazolin 1 g IM or IV
OR
Ceftriaxone 1 g IM or IV
 
Cefazolin 1 g IM or IV
OR
Ceftriaxone 1 g IM or IV
OR
Clindamycin 600 mg IM or IV

References

  1. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M; et al. (2007). "Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group". Circulation. 116 (15): 1736–54. doi:10.1161/CIRCULATIONAHA.106.183095. PMID 17446442.
  2. 2.0 2.1 "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary". Retrieved 4 March 2014.


Template:WikiDoc Sources